Back

Association between neutrophil-to-lymphocyte ratio, exercise capacity and outcomes in patients with heart failure and reduced ejection fraction

19 May 2025 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Advances in heart failure therapeutics Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Eduard Rodenas Alesina

University Hospital Vall d'Hebron, Barcelona (Spain)

4 More presentations in this session

Presentation thumbnail
Refining definitions of severe and advanced heart failure: insight from the swedish heart failure registry to optimize trial design and improve referral to advanced therapies
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase
Professor M. Petrie (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on patients' needs and perceptions
Ms R. Monroe (Charlotte, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in heart failure therapeutics

The Event

Event poster

Heart Failure 2025

19 May 2025 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Neutrophil to lymphocyte ratio as a predictor of left ventricle function and long-term mortality in patients after myocardial infarction.
thumbnail
Congress Presentation
The association between the neutrophil-to-lymphocyte ratio and the risk of chronic heart failure in obese patients following myocardial infarction
thumbnail
Congress Presentation
Neutrophil-to-lymphocyte ratio (NLR) and mortality in heart failure: analysis of population-level data

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources